Aquestive Therapeutics AQST

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.02 (+0.65%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Aquestive Therapeutics (AQST)
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $2.65

  • Market Cap

    $262.01 Million

  • Price-Earnings Ratio

    -5.20

  • Total Outstanding Shares

    98.87 Million Shares

  • Total Employees

    135

  • Dividend

    No dividend

  • IPO Date

    July 25, 2018

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    30 technology drive, Warren, NJ, 07059

  • Homepage

    https://www.aquestive.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

January 1, 2024 to December 31, 2024
MetricValue
Net Cash Flow$47.67 Million
Net Cash Flow From Investing Activities$-159,000
Net Cash Flow, Continuing$47.67 Million
Net Cash Flow From Operating Activities$-35.76 Million
Net Cash Flow From Operating Activities, Continuing$-35.76 Million
Net Cash Flow From Financing Activities, Continuing$83.59 Million

Income Statement

January 1, 2024 to December 31, 2024
MetricValue
Costs And Expenses$88.33 Million
Income/Loss From Continuing Operations After Tax$-44.14 Million
Diluted Average Shares$86.73 Million
Net Income/Loss Attributable To Noncontrolling Interest$0
Cost Of Revenue$17.87 Million
Revenues$57.56 Million

Comprehensive Income

January 1, 2024 to December 31, 2024
MetricValue
Other Comprehensive Income/Loss$-44.14 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
Comprehensive Income/Loss$-44.14 Million
Comprehensive Income/Loss Attributable To Parent$-44.14 Million

Balance Sheet

January 1, 2024 to December 31, 2024
MetricValue
Inventory$6.04 Million
Assets$101.42 Million
Long-term Debt$45 Million
Noncurrent Liabilities$142.72 Million
Accounts Payable$10.29 Million
Other Non-current Assets$9.40 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about AQST from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.